The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ...

It’s a blow for GSK, which hopes that Trelegy (fluticasone furoate+umeclidinium+vilanterol) will help to revive the fortunes of its respiratory diseases franchise. The company had been propped ...

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...

After hours: March 13 at 4:02:17 PM EDT Loading Chart for INVA ...

Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive pulmonary disease (COPD). Aside from the fact that they are ineffective for COPD, these inhalers can pose risks ...